A Live Attenuated Dengue Virus Vaccine (Dengvaxia®) is Suppressed in Individuals With Immunity to Serotype 4
The Journal of Infectious Diseases · 28.10.2026
DOI: 10.1093/infdis/jiag522 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 28.10.2026. Verfasst von Cameron Adams und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, NC, U.S. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, US National Institutes of Health, The Philippine Department of Health.
Abstract (Originalsprache)
Background
Dengvaxia® was the first live attenuated tetravalent dengue virus (DENV) vaccine to be tested and approved for use in people. While Dengvaxia® was designed to be tetravalent, in humans, the vaccine performed like a monovalent DENV4 vaccine because the DENV4 vaccine virus replicated better than other vaccine serotypes. Dengvaxia® was safe and efficacious in children who were DENV-immune at baseline (BL) and contraindicated for use in DENV-naive children.
Methods
When Dengvaxia® was rolled out as a pediatric vaccine in the Philippines in 2016, we established a prospective cohort to assess vaccine performance by BL dengue serostatus. Here, we report on how BL monotypic immunity to each serotype (reflecting one past DENV infection) impacted Dengvaxia® responses.
Results
We observed that in children with BL immunity to DENV1, 2, or 3, the vaccine stimulated a secondary serotype cross-neutralizing Ab response, which likely explains the overall favorable performance of the vaccine in seropositive children enrolled in phase 3 trials. We observed a high frequency (61%) of vaccine suppression among DENV4 monotypic immune children.
Conclusions
Our results confirm the replication dominance of the DENV4 vaccine component in Dengvaxia® and directly implicate pre-existing DENV4 immunity in the suppression of the vaccine. Our results have broader implications for evaluating the performance of other DENV vaccines in seropositive individuals.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, NC, U.S.
- Institute of Child Health and Human Development, University of the Philippines Manila, Manila, Philippines.
ORCID-Profile: Lindsay D Hein, Ruby Shah, Lakshmanane Premkumar, Michelle Ylade, Jacqueline Deen, Aravinda M de Silva
Förderung
- NIAID NIH HHS
- US National Institutes of Health
- The Philippine Department of Health
- Hanako Foundation
- Swedish International Development Cooperation Agency
- The International Vaccine Institute
Zitieren
APA
Adams, C., Hein, L. D., White, L. J., Shah, R., Premkumar, L., Daag, J. V., Agrupis, K. A., Crisostomo, M. V., Ylade, M., Deen, J., Lopez, A. L., & de Silva, A. M. (2026). A Live Attenuated Dengue Virus Vaccine (Dengvaxia®) is Suppressed in Individuals With Immunity to Serotype 4. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag522
Vancouver
Adams C, Hein LD, White LJ, Shah R, Premkumar L, Daag JV, et al. A Live Attenuated Dengue Virus Vaccine (Dengvaxia®) is Suppressed in Individuals With Immunity to Serotype 4. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag522
BibTeX
@article{Adams2026,
author = {Adams, Cameron and Hein, Lindsay D and White, Laura J and Shah, Ruby and Premkumar, Lakshmanane and Daag, Jedas Veronica and Agrupis, Kristal An and Crisostomo, Maria Vinna and Ylade, Michelle and Deen, Jacqueline and Lopez, Ana Lena and de Silva, Aravinda M},
title = {A Live Attenuated Dengue Virus Vaccine (Dengvaxia®) is Suppressed in Individuals With Immunity to Serotype 4},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag522}
}
EUVIMED